Zidong Donna Fu1, Julia Yue Cui1. 1. Department of Environmental and Occupational Health Sciences, University of Washington, Seattle WA 98105.
Abstract
Recent technological advancements including metagenomics sequencing and metabolomics have allowed the discovery of critical functions of gut microbiota in obesity, malnutrition, neurological disorders, asthma, and xenobiotic metabolism. Classification of the human gut microbiome into distinct "enterotypes" has been proposed to serve as a new paradigm for understanding the interplay between microbial variation and human disease phenotypes, as many organs are affected by gut microbiota modifications during the pathogenesis of diseases. Gut microbiota remotely interacts with liver and other metabolic organs of the host through various microbial metabolites that are absorbed into the systemic circulation. PURPOSE OF REVIEW: The present review summarizes recent literature regarding the importance of gut microbiota in modulating the physiological and pathological responses of various host organs, and describes the functions of the known microbial metabolites that are involved in this remote sensing process, with a primary focus on the gut microbiota-liver axis. RECENT FINDINGS: Under physiological conditions, gut microbiota modulates the hepatic transcriptome, proteome, and metabolome, most notably down-regulating cytochrome P450 3a mediated xenobiotic metabolism. Gut microbiome also modulates the rhythmicity in liver gene expression, likely through microbial metabolites, such as butyrate and propionate that serve as epigenetic modifiers. Additionally, the production of host hormones such as primary bile acids and glucagon like peptide 1 is altered by gut microbiota to modify intermediary metabolism of the host. SUMMARY: Dysregulation of gut microbiota is implicated in various liver diseases such as alcoholic liver disease, non-alcoholic steatohepatitis, liver cirrhosis, cholangitis, and liver cancer. Gut microbiota modifiers such as probiotics and prebiotics are increasingly recognized as novel therapeutic modalities for liver and other types of human diseases.
Recent technological advancements including metagenomics sequencing and metabolomics have allowed the discovery of critical functions of gut microbiota in obesity, malnutrition, neurological disorders, asthma, and xenobiotic metabolism. Classification of the humangut microbiome into distinct "enterotypes" has been proposed to serve as a new paradigm for understanding the interplay between microbial variation and human disease phenotypes, as many organs are affected by gut microbiota modifications during the pathogenesis of diseases. Gut microbiota remotely interacts with liver and other metabolic organs of the host through various microbial metabolites that are absorbed into the systemic circulation. PURPOSE OF REVIEW: The present review summarizes recent literature regarding the importance of gut microbiota in modulating the physiological and pathological responses of various host organs, and describes the functions of the known microbial metabolites that are involved in this remote sensing process, with a primary focus on the gut microbiota-liver axis. RECENT FINDINGS: Under physiological conditions, gut microbiota modulates the hepatic transcriptome, proteome, and metabolome, most notably down-regulating cytochrome P450 3a mediated xenobiotic metabolism. Gut microbiome also modulates the rhythmicity in liver gene expression, likely through microbial metabolites, such as butyrate and propionate that serve as epigenetic modifiers. Additionally, the production of host hormones such as primary bile acids and glucagon like peptide 1 is altered by gut microbiota to modify intermediary metabolism of the host. SUMMARY: Dysregulation of gut microbiota is implicated in various liver diseases such as alcoholic liver disease, non-alcoholic steatohepatitis, liver cirrhosis, cholangitis, and liver cancer. Gut microbiota modifiers such as probiotics and prebiotics are increasingly recognized as novel therapeutic modalities for liver and other types of human diseases.
Authors: Fredrik Bäckhed; Jill K Manchester; Clay F Semenkovich; Jeffrey I Gordon Journal: Proc Natl Acad Sci U S A Date: 2007-01-08 Impact factor: 11.205
Authors: Kurtis F Budden; Shaan L Gellatly; David L A Wood; Matthew A Cooper; Mark Morrison; Philip Hugenholtz; Philip M Hansbro Journal: Nat Rev Microbiol Date: 2016-10-03 Impact factor: 60.633
Authors: Kendle M Maslowski; Angelica T Vieira; Aylwin Ng; Jan Kranich; Frederic Sierro; Di Yu; Heidi C Schilter; Michael S Rolph; Fabienne Mackay; David Artis; Ramnik J Xavier; Mauro M Teixeira; Charles R Mackay Journal: Nature Date: 2009-10-29 Impact factor: 49.962
Authors: Martin Kummen; Kristian Holm; Jarl Andreas Anmarkrud; Ståle Nygård; Mette Vesterhus; Marte L Høivik; Marius Trøseid; Hanns-Ulrich Marschall; Erik Schrumpf; Bjørn Moum; Helge Røsjø; Pål Aukrust; Tom H Karlsen; Johannes R Hov Journal: Gut Date: 2016-02-17 Impact factor: 23.059
Authors: Bret D Wallace; Adam B Roberts; Rebecca M Pollet; James D Ingle; Kristen A Biernat; Samuel J Pellock; Madhu Kumar Venkatesh; Leah Guthrie; Sara K O'Neal; Sara J Robinson; Makani Dollinger; Esteban Figueroa; Sarah R McShane; Rachel D Cohen; Jian Jin; Stephen V Frye; William C Zamboni; Charles Pepe-Ranney; Sridhar Mani; Libusha Kelly; Matthew R Redinbo Journal: Chem Biol Date: 2015-09-10
Authors: Joseph L Dempsey; Dongfang Wang; Gunseli Siginir; Qiang Fei; Daniel Raftery; Haiwei Gu; Julia Yue Cui Journal: Toxicol Sci Date: 2019-03-01 Impact factor: 4.849
Authors: Kim B Pedersen; Casey F Pulliam; Aarshvi Patel; Fabio Del Piero; Tatiane T N Watanabe; Umesh D Wankhade; Kartik Shankar; Chindo Hicks; Martin J Ronis Journal: Carcinogenesis Date: 2019-04-29 Impact factor: 4.944
Authors: Emily J Cox; Dan-Dan Tian; John D Clarke; Allan E Rettie; Jashvant D Unadkat; Kenneth E Thummel; Jeannine S McCune; Mary F Paine Journal: Pharmacol Rev Date: 2021-04 Impact factor: 25.468
Authors: María Callejo; Gema Mondejar-Parreño; Bianca Barreira; José L Izquierdo-Garcia; Daniel Morales-Cano; Sergio Esquivel-Ruiz; Laura Moreno; Ángel Cogolludo; Juan Duarte; Francisco Perez-Vizcaino Journal: Sci Rep Date: 2018-06-26 Impact factor: 4.379